^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    QL301

    i
    Other names: QL301, QLF31907, QL-301, QL 301, QLF-31907, QLF 31907
    Associations

    News

    Trials
    Company:
    Qilu Pharma
    Drug class:
    PD-L1 inhibitor, CD137 agonist
    Related drugs:
    Associations

    News

    Trials
    8ms
    A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=60, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P1/2 trial • Combination therapy • Metastases
    |
    docetaxel • irinotecan • QL301
    11ms
    A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=54, Recruiting, Qilu Pharmaceutical Co., Ltd. | Trial completion date: Sep 2022 --> Jun 2024 | Trial primary completion date: Jul 2022 --> Mar 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    QL301
    over1year
    Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=66, Recruiting, Qilu Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    QL301
    3years
    A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=54, Recruiting, Qilu Pharmaceutical Co., Ltd.
    Clinical • New P1 trial
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    QL301